AGILYSYS MOVES HQ TO NEW ALPHARETTA LOCATION

TL;DR

**AGYS changed its HQ address, signaling potential operational shifts.**

AI Summary

Agilysys, Inc. filed an 8-K on January 23, 2024, to update its principal executive offices from 1000 Windward Concourse, Suite 250, Alpharetta, GA 30005 to 3655 Brookside Parkway, Suite 300, Alpharetta, Georgia 30022. This change, while seemingly minor, indicates a physical relocation of their main operations, which could reflect growth, consolidation, or a strategic move to a more suitable location. For investors, this matters as it signals operational changes that might impact overhead costs or employee logistics, potentially affecting future financial performance.

Why It Matters

This filing indicates a change in Agilysys's physical headquarters, which could signify operational adjustments, growth, or cost-saving initiatives. Investors should note this as it might impact the company's operational efficiency and future expenses.

Risk Assessment

Risk Level: low — The filing only reports a change of address, which is a routine administrative update and does not inherently pose significant financial risk.

Analyst Insight

A smart investor would note this administrative change but recognize it likely has minimal direct impact on the company's financial health or stock performance. It might warrant a quick check for any accompanying press releases that explain the 'why' behind the move, but otherwise, it's not a primary driver for investment decisions.

Key Players & Entities

• AGILYSYS, INC. (company) — the registrant filing the 8-K
• Alpharetta, Georgia (location) — city and state of both old and new principal executive offices
• 3655 Brookside Parkway Suite 300 (location) — new principal executive offices address
• 1000 Windward Concourse Suite 250 (location) — former principal executive offices address
• January 23, 2024 (date) — date of earliest event reported and filing date

Forward-Looking Statements

• The new office location may lead to minor changes in operational costs. (AGILYSYS, INC.) — medium confidence, target: 2024-12-31

FAQ

Filing Documents

• agys-20240123.htm (8-K) — 39KB
• 0000950170-24-006263.txt ( ) — 150KB
• agys-20240123.xsd (EX-101.SCH) — 24KB
• agys-20240123_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. Ramesh Srinivasan, President and Chief Executive Officer of Agilysys, Inc. (the “Company” or “Agilysys”), confirmed today that he intends to adopt a stock trading plan (the “Plan”) pursuant to which he currently plans to sell up to 300,000 shares of Agilysys common stock, most or all of which are expected to be issued upon his exercise of Stock-Settled Appreciation Rights (the “Vested SSARs”), which were awarded to him on February 10, 2020 and expire on August 10, 2024. Mr. Srinivasan and his wife, Sujatha Srinivasan, have planned the sale for financial diversification, to generate funds for upcoming tax payments, to fund the trusts they have created for their children, to fund charitable contributions and for other personal purposes. This will be the first such sale of shares of Agilysys common stock by Mr. Srinivasan during his tenure with the Company, other than approximately 70,000 shares of Agilysys common stock sold in June 2021 to fund withholding tax obligations arising from the exercise of SSARs prior to expiration. Mr. Srinivasan currently intends to retain all other shares of Agilysys common stock he currently holds, including the shares of Agilysys common stock he purchased in the market between February 2017 and March 2020. Mr. Srinivasan continues to believe that the Company’s future prospects are strong, and his stake in the Company will continue to remain very significant. In addition to the shares of Agilysys common stock Ramesh and Sujatha Srinivasan currently hold, Mr. Srinivasan continues to hold unvested restricted stock units awarded to him in connection with his employment agreement signed on March 10, 2023. Mr. Srinivasan will exercise the Vested SSARs and sell the shares under the Plan in accordance with guidelines specified under Rule 10b5-1 of the Securities and Exchange Act of 1934. He anticipates that sales under the Plan will occur between April

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. d. Exhibits. The following item is furnished as an exhibit to this current report on Form 8-K: Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGILYSYS, INC. Date: January 23, 2024 By: /s/ Kyle C. Badger Kyle C. Badger Senior Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR